▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / JAGX

JAGX — Jaguar Health, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1585608 ·
Last close
$0.91
Market Cap
$4.48M
52W High
$3.66
52W Low
$0.73
ADV30
161,049
Next earnings
2026-11-12
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 20,247,000 19,089,000 10,182,000 8,849,000 37,434,000 7,278,000 53,186,000
Dec 2025 3,235,000 1,035,000 -20,442,000 -23,061,000 38,323,000 968,000 57,011,000
Sep 2025 3,083,000 2,551,000 -7,238,000 -9,502,000 49,472,000 3,527,000 45,113,000
Jun 2025 2,979,000 2,452,000 -8,007,000 -10,407,000 48,268,000 2,207,000 41,388,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,542,000
Investing CF
$-256,000
Financing CF
$12,089,000
CapEx
$-215,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1639.35
As of
2026-08-23

Balance + Analyst (yfinance extras)

Retained Earnings
$-391,067,000
Inventory
$7,819,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-35,087,000
Pretax Income TTM
$-34,678,000
Interest Exp TTM
$699,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$27,815,000
EBITDA
$-23,193,000
Free Cash Flow
$-2,115,125
Enterprise Value
$17,305,500
Total Cash
$3,788,000
Total Debt
$16,651,000
Shares Out
4,910,402
Trailing EPS
$-695.50
Book Value
$-99.20
ROE
-548.8%
ROA
-38.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 11,511,000 -45,108,000 -53,434,000 38,323,000 57,011,000 — -23,686,000
Dec 2024 11,689,000 -30,831,000 -38,492,000 53,425,000 46,931,000 — -29,384,000
Dec 2023 9,761,000 -33,920,000 -41,300,000 50,763,000 45,866,000 — -33,242,000
Dec 2022 11,956,000 -34,415,000 -47,454,000 47,452,000 48,808,000 — -33,104,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.68

Peers — same industry

TickerNameMarket CapLastDaily %
SBFM Sunshine Biopharma Inc. $4.50M $1.16 —
REVB REVELATION BIOSCIENCES, INC. $4.38M $1.10 —
TCRT Alaunos Therapeutics, Inc. $4.37M $1.72 —
LIANY LianBio $4.37M $0.04 —
JUNS JUPITER NEUROSCIENCES, INC. $4.36M $5.66 —

News headlines (Yahoo Finance, 1h cache)

Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...
2026-08-20 05:02 · Yahoo
Jaguar Health Reports Second Quarter 2026 Financials
2026-08-19 20:00 · Yahoo
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
2026-08-05 13:00 · Yahoo
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
2026-07-28 13:00 · Yahoo
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
2026-06-30 13:00 · Yahoo
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
2026-06-25 13:00 · Yahoo
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2026-06-23 13:00 · Yahoo
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
2026-06-22 13:00 · Yahoo
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
2026-06-18 13:00 · Yahoo
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
2026-06-08 20:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →